Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Warren Allen

Cytopathology Santa Monica, CA Medical Doctor

NPI 1801850722 CMS profile 1155121

1328 22Nd St, Santa Monica, CA 90404

Open in the dashboard

General payments

$118

6 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Warren Allen of Santa Monica, CA is reported in the CMS Open Payments database as having received $118 across 6 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Cytopathology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43 2
2024 General $34 2
2021 General $20 1
2019 General $22 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Warren Allen
  • Cytopathology median
  • Middle half of Cytopathology
  • National median

In program year 2025, general payments to Warren Allen were reported at $43. Among 60 Cytopathology profiles paid that year, the median was $56 and the middle half received between $24 and $145.

Show as a table
Year Warren Allen Cytopathology median Middle half National median
2019 $22 $52 $21–$145 $163
2020 $0 $47 $22–$379 $114
2021 $20 $28 $18–$101 $132
2022 $0 $86 $24–$153 $149
2023 $0 $51 $23–$125 $160
2024 $34 $36 $20–$204 $164
2025 $43 $56 $24–$145 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Cepheid $36 2 payments
  2. Siemens Medical Solutions USA, Inc. $36 2 payments
  3. Caris MPI, Inc. $25 1 payment
  4. Roche Diagnostics Corporation $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $118 6 payments
Products named General payments · program years 2019–2025
  1. GeneXpert $36 2 payments
  2. MI CANCER SEEK $25 1 payment
  3. TD VENTANA Workflow Solutions $22 1 payment
  4. Atellica CH 930 Analyzer $20 1 payment
  5. Atellica IM 1300 Analyzer $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$94,878

Medicare's payments for the services billed

Medicare patients

677

Average age 76

Services billed

2,205

312 women, 365 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 55%
Ischemic heart disease 42%
Cancer 41%
Diabetes 25%
Osteoporosis 24%
Atrial fibrillation 22%
Chronic kidney disease 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

6 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cytopathology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record